Literature DB >> 3018528

A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components.

D Reisman, J Yates, B Sugden.   

Abstract

A genetic element of Epstein-Barr virus, oriP, when present on recombinant plasmids allows those plasmids to replicate and to be maintained in cells that express the Epstein-Barr virus-encoded nuclear antigen EBNA-1. Here we define the DNA sequences required for oriP activity. Two noncontiguous regions of oriP are required in cis for activity. One consists of approximately 20 tandem, imperfect copies of a 30-base-pair (bp) sequence. The other required region, approximately 1,000 bp away, is at most 114 bp in length and contains a 65-bp region of dyad symmetry. When present together on a plasmid, these two components supported plasmid replication even when the distance between them was varied or their relative orientation was altered, or both. When present alone on a plasmid that expresses a selectable marker, the family of 30-bp repeats efficiently conferred a transient drug-resistant phenotype in human 143 cells that is dependent on the presence of EBNA-1. This result leads us to suggest that EBNA-1 interacts with the 30-bp repeated sequence to activate oriP. To test whether the 30-bp repeats might cause the increased transient expression of drug resistance by enhancing transcription, the family of 30-bp repeats was tested for the ability to activate the simian virus 40 early promoter present in plasmid pA10CAT2 (Laimins, et al., Proc. Natl. Acad. Sci. U.S.A. 79:6453-6457). In this assay, the 30-bp repeats could activate the simian virus 40 early promoter in Raji cells, an EBNA-positive Burkitt's lymphoma cell line, but not detectably an EBNA-positive 143 cells in which oriP also functions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3018528      PMCID: PMC366897          DOI: 10.1128/mcb.5.8.1822-1832.1985

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  Epstein-Barr virus DNA is amplified in transformed lymphocytes.

Authors:  B Sugden; M Phelps; J Domoradzki
Journal:  J Virol       Date:  1979-09       Impact factor: 5.103

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Mutational analysis of the simian virus 40 replicon: pseudorevertants of mutants with a defective replication origin.

Authors:  D R Shortle; R F Margolskee; D Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

4.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

5.  A simple, rapid, and sensitive DNA assay procedure.

Authors:  C Labarca; K Paigen
Journal:  Anal Biochem       Date:  1980-03-01       Impact factor: 3.365

6.  Nucleotide sequence of a fragment of HeLa-cell mitochondrial DNA containing the precisely localized origin of replication.

Authors:  G Attardi; S T Crews; J Nishiguchi; D K Ojala; J W Posakony
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1979

7.  DNA fragments from F9 PyEC mutants increase expression of heterologous genes in transfected F9 cells.

Authors:  E Linney; S Donerly
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

8.  Characterization of the TRS/IRS origin of DNA replication of herpes simplex virus type 1.

Authors:  N D Stow; E C McMonagle
Journal:  Virology       Date:  1983-10-30       Impact factor: 3.616

9.  Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.

Authors:  J L Yates; N Warren; B Sugden
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

10.  Trans-complementation-dependent replication of a low molecular weight origin fragment from plasmid R6K.

Authors:  R Kolter; M Inuzuka; D R Helinski
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

View more
  200 in total

1.  Establishment of a chemical synthetic lethality screen in cultured human cells.

Authors:  A Simons; N Dafni; I Dotan; Y Oron; D Canaani
Journal:  Genome Res       Date:  2001-02       Impact factor: 9.043

2.  An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency.

Authors:  B T Tan; L Wu; A J Berk
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus.

Authors:  D F Ceccarelli; L Frappier
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 4.  Gammaherpesviruses and "Hit-and-Run" oncogenesis.

Authors:  R F Ambinder
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

5.  Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus.

Authors:  M A Lee; M E Diamond; J L Yates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  The linking regions of EBNA1 are essential for its support of replication and transcription.

Authors:  D Mackey; B Sugden
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

7.  Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth.

Authors:  M S Kang; S C Hung; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

8.  Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1.

Authors:  Hong Wu; Priya Kapoor; Lori Frappier
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

9.  The cis-acting family of repeats can inhibit as well as stimulate establishment of an oriP replicon.

Authors:  E R Leight; B Sugden; E R Light
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  The replicator of the Epstein-Barr virus latent cycle origin of DNA replication, oriP, is composed of multiple functional elements.

Authors:  M D Koons; S Van Scoy; J Hearing
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.